Questcor Execs Hid Athcor Woes To Pad Price, Suit Says

Law360, New York (October 12, 2012, 5:47 PM EDT) -- A Questcor Pharmaceuticals Inc. shareholder on Thursday lodged a derivative complaint against the company's top executives, accusing them of lying about the efficacy of their main drug to inflate the price of the company's stock shortly before Aetna Inc. reduced reimbursements for it.

Plaintiff James Tripoli alleges Questcor's president and CEO Don M. Bailey, chief financial officer Michael H. Mulroy, chief operating officer Stephen L. Cartt and eight other officers and directors misrepresented the value of Athcar, which can be prescribed for 19 different problems including...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

James Tripoli v. Don M Bailey et al


Case Number

8:12-cv-01759

Court

California Central

Nature of Suit

Stockholders Suits

Judge

Dolly M. Gee

Date Filed

October 11, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.